|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, our results elucidated for the first time that TIPE2 sensitizes osteosarcoma cells to cis-platin through downregulation of MDR1 and may be a novel target in osteosarcoma therapy.
|
30114619 |
2018 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells.
|
28693150 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that multidrug resistant osteosarcoma cells are able to spread their ability to resist the effects of doxorubicin treatment on sensitive cells by transferring exosomes carrying MDR-1 mRNA and its product P-glycoprotein.
|
27176642 |
2016 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, icariin possesses a reversal effect on multidrug resistance in MG-63/DOX cells through down-regulation of the MDR1 and the PI3K/Akt pathway, and has the potential to be an adjunct to chemotherapy for osteosarcoma.
|
25747987 |
2015 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data demonstrate a role for Trps1 in the regulation of MDR1 expression in osteosarcoma.
|
24491996 |
2014 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overexpression of the mdr1 gene encoding P-glycoprotein (Pgp) exerts a major role in reducing the effectiveness of cytotoxic therapy in osteosarcoma.
|
21780101 |
2012 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines.
|
21868524 |
2011 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the osteosarcoma cell lines, etoposide and doxorubicin were better inducers of P450 3A4 and MDR1 than rifampin. siRNA against PXR down-regulated P450 3A4 expression only in the osteosarcoma cell line.
|
17279585 |
2007 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study the U2OS human osteosarcoma cell line and its multidrug resistant (MDR) subline that overexpresses MDR-1 gene, MDR-U2OS, have been analyzed for their responsiveness to TRAIL.
|
15547696 |
2004 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes.
|
12695554 |
2003 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study represents the first prospective assessment of the prognostic value of MDR1 mRNA expression in patients with newly diagnosed extremity osteosarcoma.
|
10894867 |
2000 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Point mutations in the MDR1 promoter have been found in osteogenic sarcoma (Stein et al., Eur J of Cancer, 30A: 1541-1545, 1994).
|
10500782 |
1999 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed the subcellular localization of P-glycoprotein, in a series of U-2 OS osteosarcoma cell clones transfected with MDR1 gene in order to verify whether the nucleus is a constant site for the localization and functional activity of P-glycoprotein, and in which way some aspects of cell morphology related to MDR depend on the subcellular P-glycoprotein localization rather than on the exposure to the selective drug.
|
10321019 |
1999 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear expression of YB-1 is correlated with MDR-1 gene expression in breast cancer and osteosarcoma.
|
10597187 |
1999 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MDR1 gene-transfected osteosarcoma cell clones, showing different levels of P-glycoprotein expression, were analysed for their in vitro characteristics and their tumorigenic and metastatic ability in athymic mice.
|
9989824 |
1999 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that P-Gp/MDR1 overexpression is related to multidrug resistance in human osteosarcoma in vivo.
|
9458350 |
1998 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, many osteosarcomas exhibited intrinsic expression of MDR1 mRNA before multidrug regimens which invariably included doxorubicin and, in most cases, MDR1 expression was not induced following chemotherapeutic treatment.
|
8855972 |
1996 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We have shown previously that overexpression of the MDR1 gene product P-glycoprotein is the most important predictor of an adverse clinical course in patients with osteosarcoma. treated with chemotherapy.
|
8625324 |
1996 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Resistance to several cytotoxic agents (MultiDrug Resistance MDR), including anthracyclines, vinca alkaloids and epipodophylline derivatives can occur in human osteosarcoma (OS) cells, detected by the overexpression of a 170 kD glycoprotein (p170), as a result of increased expression of the MDR gene (mdr1).
|
8669809 |
1996 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Three osteosarcomas with undetectable levels of mdr-1 expression by RT-PCR were negative immunohistochemically.
|
7735558 |
1995 |
|
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A comparative polymerase chain reaction (PCR)-based sequence analysis of the mdr1 promoter revealed point mutations in seven out of nine osteosarcomas at nucleotides +103 (2 cases T-->C) and +137 (5 cases G-->T).No changes were seen in eight MFHs.
|
7833115 |
1994 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An intermediate mdr1 expression was observed most frequently, with the exception of osteosarcomas (high) and malignant fibrous histiocytomas (low).
|
7904171 |
1993 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results of this pilot study suggest that a larger scale prospective investigation of the effect of mdr1 gene expression on outcome in osteosarcoma is warranted.
|
8100852 |
1993 |